Daniel S. Peeper

20082019
If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2008 2019

  • 24 Article
  • 4 Research external, graduation VU University Amsterdam
  • 3 Research VU University Amsterdam, graduation VU University Amsterdam

Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in nonsmall cell lung cancer

Theelen, W. S. M. E., Kuilman, T., Schulze, K., Zou, W., Krijgsman, O., Peters, D. D. G. C., Cornelissen, S., Monkhorst, K., Sarma, P., Sumiyoshi, T., Amler, L. C., Willems, S. M., Blaauwgeers, J. L. G., van Noesel, C. J. M., Peeper, D. S., van den Heuvel, M. M. & Kowanetz, M., 2019, In : PLoS ONE. 14, 5, e0216864.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

Augmenting Immunotherapy Impact by Lowering Tumor TNF Cytotoxicity Threshold

Vredevoogd, D. W., Kuilman, T., Ligtenberg, M. A., Boshuizen, J., Stecker, K. E., de Bruijn, B., Krijgsman, O., Huang, X., Kenski, J. C. N., Lacroix, R., Mezzadra, R., Gomez-Eerland, R., Yildiz, M., Dagidir, I., Apriamashvili, G., Zandhuis, N., van der Noort, V., Visser, N. L., Blank, C. U., Altelaar, M. & 2 othersSchumacher, T. N. & Peeper, D. S., 2019, In : Cell. 178, 3, p. 585-599.e15

Research output: Contribution to journalArticleAcademicpeer-review

Frequent clonal relations between metastases and non-index prostate cancer lesions

Kneppers, J., Krijgsman, O., Melis, M., de Jong, J., Peeper, D. S., Bekers, E., van der Poel, H. G., Zwart, W. & Bergman, A. M., 2019, In : JCI Insight. 4, 2, Y.

Research output: Contribution to journalArticleAcademicpeer-review

Open Access

Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial

Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Adhikari, C., Bierman, C., van de Wiel, B. A., Scolyer, R. A., Krijgsman, O., Sikorska, K., Eriksson, H., Broeks, A., van Thienen, J. V., Guminski, A. D., Acosta, A. T., ter Meulen, S., Koenen, A. M., Bosch, L. J. W., Shannon, K., Pronk, L. M., Gonzalez, M. & 17 othersCh'ng, S., Grijpink-Ongering, L. G., Stretch, J., Heijmink, S., van Tinteren, H., Haanen, J. B. A. G., Nieweg, O. E., Klop, W. M. C., Zuur, C. L., Saw, R. P. M., van Houdt, W. J., Peeper, D. S., Spillane, A. J., Hansson, J., Schumacher, T. N., Long, G. V. & Blank, C. U., 2019, In : The Lancet Oncology. 20, 7, p. 948-960

Research output: Contribution to journalArticleAcademicpeer-review

In vivo ERK1/2 reporter predictively models response and resistance to combined BRAF and MEK inhibitors in melanoma

Sanchez, I. M., Purwin, T. J., Chervoneva, I., Erkes, D. A., Nguyen, M. Q., Davies, M. A., Nathanson, K. L., Kemper, K., Peeper, D. S. & Aplin, A. E., 2019, In : Molecular Cancer Therapeutics. 18, 9, p. 1637-1648

Research output: Contribution to journalArticleAcademicpeer-review